Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Economopoulou, V. Kaklamani, K. Siziopikou (2012)
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies.The oncologist, 17 11
J. Visvader, G. Lindeman (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questionsNature Reviews Cancer, 8
B. Patel, Yingjie Yu, Jianhua Du, E. Levi, P. Phillip, A. Majumdar (2009)
Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: a risk factor for colon cancer.Biochemical and biophysical research communications, 378 3
F. Gambelli, F. Sasdelli, Ivana Manini, C. Gambarana, G. Oliveri, C. Miracco, V. Sorrentino (2012)
Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin‐1 expressionCell Biology International, 36
V. Wielenga, R. Voort, J. Mulder, P. Kruyt, W. Weidema, J. Oosting, C. Seldenrijk, C. Krimpen, G. Offerhaus, S. Pals (1998)
CD44 splice variants as prognostic markers in colorectal cancer.Scandinavian journal of gastroenterology, 33 1
Wilko Weichert, T. Knösel, J. Bellach, M. Dietel, G. Kristiansen (2004)
ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survivalJournal of Clinical Pathology, 57
C. Cox, P. Diamanti, R. Evely, P. Kearns, A. Blair (2009)
Expression of CD133 on leukemia-initiating cells in childhood ALL.Blood, 113 14
C. D’Alterio, L. Cindolo, L. Portella, Marianeve Polimeno, C. Consales, A. Riccio, M. Cioffi, R. Franco, P. Chiodini, G. Cartenì, V. Mirone, N. Longo, L. Marra, S. Perdoná, L. Claudio, M. Mascolo, S. Staibano, M. Falsaperla, M. Puglisi, G. Martignoni, V. Ficarra, G. Castello, S. Scala (2010)
Differential role of CD133 and CXCR4 in renal cell carcinomaCell Cycle, 9
M. Trerotola, S. Rathore, H. Goel, Jing Li, S. Alberti, M. Piantelli, Dave Adams, Zhong Jiang, L. Languino (2010)
CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells.American journal of translational research, 2 2
L. Finke, H. Terpe, C. Zörb, W. Haensch, P. Schlag, D. Parker (1995)
Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteinsThe Lancet, 345
C. Ginestier, M. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, Marty Brown, J. Jacquemier, P. Viens, C. Kleer, Suling Liu, A. Schott, D. Hayes, D. Birnbaum, M. Wicha, G. Dontu (2007)
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.Cell stem cell, 1 5
D. Horst, Lydia Kriegl, J. Engel, T. Kirchner, A. Jung (2009)
Prognostic Significance of the Cancer Stem Cell Markers CD133, CD44, and CD166 in Colorectal CancerCancer Investigation, 27
J. Hatina (2012)
The dynamics of cancer stem cells.Neoplasma, 59 6
M. Koukourakis, A. Giatromanolaki, V. Tsakmaki, V. Danielidis, E. Sivridis (2012)
Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head–neck cancerBritish Journal of Cancer, 106
J. McNamara (2007)
Cancer Stem Cells
M. Morrin, P. Delaney (2002)
CD44v6 is not relevant in colorectal tumour progressionInternational Journal of Colorectal Disease, 17
Hironobu Kawamoto, Takeshi Yuasa, Yasuhiro Kubota, M. Seita, H. Sasamoto, Javed Shahid, Takahiro Hayashi, H. Nakahara, Reham Hassan, M. Iwamuro, E. Kondo, S. Nakaji, N. Tanaka, N. Kobayashi (2010)
Characteristics of CD133+ Human Colon Cancer SW620 CellsCell Transplantation, 19
A. Dimou, V. Neumeister, S. Agarwal, V. Anagnostou, K. Syrigos, D. Rimm (2012)
Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer.The American journal of pathology, 181 4
G. Galizia, Marica Gemei, L. Vecchio, A. Zamboli, R. Noto, P. Mirabelli, F. Salvatore, P. Castellano, M. Orditura, F. Vita, Margherita Pinto, C. Pignatelli, E. Lieto (2012)
Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer.Archives of surgery, 147 1
A. Lugli, G. Iezzi, I. Hostettler, M. Muraro, V. Mele, L. Tornillo, Vincenza Carafa, G. Spagnoli, L. Terracciano, I. Zlobec (2010)
Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancerBritish Journal of Cancer, 103
C. Kahlert, F. Bergmann, Janine Beck, T. Welsch, C. Mogler, E. Herpel, Shamik Dutta, Thomas Niemietz, M. Koch, J. Weitz (2011)
Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancerBMC Cancer, 11
Yuta Wakamatsu, N. Sakamoto, H. Oo, Yutaka Naito, N. Uraoka, Katsuhiro Anami, K. Sentani, N. Oue, W. Yasui (2012)
Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancerPathology International, 62
Neng-yi Hou, Kun Yang, Tie Chen, Xin-Zu Chen, Bo Zhang, X. Mo, Jian-kun Hu (2011)
CD133+CD44+ subgroups may be human small intestinal stem cellsMolecular Biology Reports, 38
T. Vogler, Lydia Kriegl, D. Horst, J. Engel, S. Sagebiel, A. Schäffauer, T. Kirchner, A. Jung (2012)
The expression pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent prognostic marker for low survival in colorectal tumors.Experimental and molecular pathology, 92 1
Xiao-Han Huang, Yu Sheng, Ming Guan (2012)
Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.Surgical oncology, 21 2
Williams (2012)
Cancer stem cells.Clin Lab Sci, 25
Hee-kyung Chang, E. Yu, Jihun Kim, Y. Bae, K. Jang, E. Jung, G. Yoon, J. Kim, Y. Oh, H. Bae, Gwang Kim, S. Jung, M. Gu, Jung Kim, K. Jang, S. Jun, D. Eom, K. Kwon, G. Kang, Jae Park, Soonwon Hong, J. Lee, Jason Park, Seung‐Mo Hong (2010)
Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases.Human pathology, 41 8
Shan Deng, Xiaojun Yang, H. Lassus, Shun Liang, S. Kaur, Q. Ye, Chunsheng Li, Li-ping Wang, K. Roby, S. Orsulic, D. Connolly, Youcheng Zhang, K. Montone, R. Bützow, G. Coukos, Lin Zhang (2010)
Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial CancersPLoS ONE, 5
M. Tachezy, H. Zander, F. Gebauer, A. Marx, J. Kaifi, J. Izbicki, M. Bockhorn (2012)
Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.The Journal of surgical research, 177 1
K. Penumatsa, S. Edassery, A. Barua, M. Bradaric, J. Luborsky (2010)
Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumorsJournal of Ovarian Research, 3
K. Endo, T. Terada (2000)
Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival.Journal of hepatology, 32 1
(2010)
Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells
RESEARCH ARTICLE Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma Dae-Woon Eom, MD, PhD,* Seung-Mo Hong, MD, PhD,w Gwangil Kim, MD, PhD,z Young Kyung Bae, MD, PhD,y Kee-Taek Jang, MD, PhD,8 and Eunsil Yu, MD, PhDw rimary small intestinal adenocarcinoma (SIAC) is an Background: Small intestinal adenocarcinoma (SIAC) is a rare Pextremely rare tumor, although the small intestine human malignant tumor. According to the cancer stem cell accounts for one of the largest surface areas in the human (CSC) hypothesis, only a small subpopulation of tumor cells has body, occupying about 90% of the absorptive surface the ability to initiate and increase tumor growth. CD44v6, area of the gastrointestinal tract. Despite recent advances CD133, CD166, and ALDH1 have been proposed to be putative in endoscopic modalities and imaging techniques for ap- CSC markers in gastrointestinal malignancies. However, their proaching the small intestine, early detection of SIACs is implications in SIAC still remain unclear. We aimed to inves- quite difficult and the 5-year survival rate of SIACs di- tigate the expressions of CD44v6, CD133, CD166, and ALDH1 1 agnosed in the advanced disease state is 41.2%. There is and evaluate their relationships with clinicopathologic para-
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Feb 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.